SEC Form 10-Q filed by IDEAYA Biosciences Inc.
Unavailable
Unavailable
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/22/2025 | Buy | TD Cowen | |
7/10/2025 | $25.00 | Neutral | Goldman |
6/26/2025 | $44.00 | Overweight | Wells Fargo |
11/18/2024 | $51.00 | Overweight | Stephens |
11/5/2024 | $27.00 | Outperform → Market Perform | Leerink Partners |
10/24/2024 | $50.00 | Buy | UBS |
10/15/2024 | Overweight | Cantor Fitzgerald | |
7/8/2024 | $50.00 | Outperform | Mizuho |
TD Cowen initiated coverage of IDEAYA Biosciences with a rating of Buy
Goldman resumed coverage of IDEAYA Biosciences with a rating of Neutral and set a new price target of $25.00
Wells Fargo initiated coverage of IDEAYA Biosciences with a rating of Overweight and set a new price target of $44.00
3 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)
4 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)
4 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)
The presentation will include data from over 90 patients in both the plaque brachytherapy and enucleation-eligible cohortsDarovasertib has received U.S. FDA Breakthrough Therapy Designation for use in neoadjuvant uveal melanoma for subjects requiring enucleationInitiated a multi-site, global randomized Phase 3 neoadjuvant registrational trial in primary uveal melanoma (OptimUM-10) in Q3 2025SOUTH SAN FRANCISCO, Calif., July 24, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a leading precision medicine oncology company, today announced that results from a multi-site global Phase 2 study of neoadjuvant darovasertib in primary uveal melanoma was accepted for a Proffered Paper ora
SOUTH SAN FRANCISCO, Calif., July 23, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced it will host an in-person and virtual R&D Day on September 8, 2025 from 8:00am to 10:00am ET in New York City to present multiple clinical data updates across the pipeline and highlight the next key drivers of growth and upcoming milestones. "This year marks IDEAYA's ten-year anniversary since our founding, and we look forward to providing multiple clinical data up
Clinical efficacy and safety data will be presented from over 70 small-cell lung cancer (SCLC) patients in Hengrui's ongoing, multi-site, open label Phase 1 trialData will include patients from the dose escalation and at multiple expansion dosesU.S. Phase 1 trial of IDE849 in SCLC patients initiated in 3Q 2025JIANGSU, China and SOUTH SAN FRANCISCO, Calif., July 22, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a leading precision medicine oncology company, and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui), a global pharmaceutical company focused on scientific and technological innovation, today announced the publication of an abstract for an oral presentation on IDE849 (
8-K - IDEAYA Biosciences, Inc. (0001676725) (Filer)
8-K - IDEAYA Biosciences, Inc. (0001676725) (Filer)
SCHEDULE 13G - IDEAYA Biosciences, Inc. (0001676725) (Subject)
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the appointment of Joshua Bleharski, Ph.D. as Chief Financial Officer. Dr. Bleharski joins IDEAYA from J.P. Morgan, where he spent nearly 17 years advising clients in the biopharma sector on capital markets transactions, corporate strategy and other investment banking services. IDEAYA anticipates that Dr. Bleharski will complete the transition into his new role by early May.
Brings over 20-year global commercialization experience in oncology with leading biopharmaceutical companies Gilead Sciences and Bristol Myers Squibb, including leadership of multiple commercial launches for products including Trodelvy® and Opdivo®SOUTH SAN FRANCISCO, Calif., Nov. 18, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the appointment of Stu Dorman as Chief Commercial Officer. Mr. Dorman has a track record of commercial success in numerous specialty disease areas with over 20 years of oncology and hematology experience.
Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, Actelion Pharmaceuticals, Eisai, GSK, and the U.S. FDASOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that Douglas B. Snyder, joined the company as its Senior Vice President, General Counsel on September 18, 2024. "Doug brings a broad legal background in the healthcare field spanning biotechnology, pharm
SC 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)
SC 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)
SC 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)
Phase 2 company-sponsored and IST neoadjuvant uveal melanoma (UM) clinical data update in 49 evaluable patients, demonstrates ~49% of patients with >30% tumor shrinkage by product of diameters, and ~61% eye preservation rate for enucleation patientsTargeting to initiate Phase 3 randomized registrational trial in neoadjuvant UM following finalization of the clinical protocol with FDAClinical endpoints supportive of full approval based on FDA guidance: Eye preservation rate as the primary endpoint for enucleation patients. Time to vision loss as the primary endpoint for plaque brachytherapy patients. No detriment to Event-Free-Survival (EFS) in the treatment arms is a secondary endpointDiscuss
SOUTH SAN FRANCISCO, Calif., Sept. 22, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that the company plans to issue a pre-market press release and conduct an investor webcast on Monday, September 23, 2024, at 8:00 a.m. ET to report interim Phase 2 data for darovasertib and provide a regulatory update from FDA Type C meeting in neoadjuvant uveal melanoma (UM). Darovasertib is a potent and selective protein kinase C (PKC) inhibitor being developed to broadly address primary and metastatic UM.
~39% Overall Response Rate (ORR): 1 CR and 6 PRs (2 awaiting confirmation) by RECIST 1.1 out of 18 evaluable MTAP-deletion urothelial and NSCLC patients~94% Disease Control Rate (DCR): 1 CR and 6 PRs and 10 SD by RECIST 1.1~78% of Patients with Tumor Shrinkage: 14 patients observed tumor shrinkage~81% ctDNA Molecular Response Rate (MRR): 13 of 16 patients with > 50% ctDNA reductionAE Profile: ~5.6% drug-related grade >3 AEs and no drug-related SAEs or discontinuations at 30 mg once-a-day expansion doseIDE397 expansion dose of 30 mg once-a-day achieved target drug coverage and plasma SAM pharmacodynamic reduction associated with preclinical tumor regressions~48k U.S. annual incidence of MTAP-